跳到正文
实时
TechCrunch · AI· Ram Iyer·· 54 分钟前

Isomorphic Labs融资50亿美元,目标是将AI药物候选物推进临床试验

Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials

要点速览

Isomorphic Labs宣布完成50亿美元C轮融资,旨在将AI药物候选物推进临床试验;新资金将用于开发药物设计引擎并拓展更多药物类型,此前已获得21亿美元B轮融资。公司基于DeepMind的AlphaFold模型开发药物设计技术,已在肿瘤学和免疫学领域取得“积极临床前结果”,并与礼来、诺华、强生等药企达成合作。

同一件事另外 2 家也报道了

  1. IT之家 · AI··首发

    Alphabet 旗下药物 AI 企业 Isomorphic Labs 完成 50 亿美元 C 轮融资

  2. TechCrunch · AI··+1 小时 11 分·当前阅读

    Isomorphic Labs融资50亿美元,目标是将AI药物候选物推进临床试验

    新增信息:TechCrunch 提及公司基于 DeepMind 的 AlphaFold 模型,并在肿瘤学和免疫学领域取得“积极临床前结果”。

  3. The Decoder··+1 小时 18 分

    Isomorphic Labs 完成第二轮 50 亿美元融资

    新增信息:The Decoder 提及融资在六个月内完成。

按发布时间排列 · 事件后续出现时自动追加 · 由模型根据各家标题与摘要比对

正文

In Brief

Posted:

6:50 AM PST · November 17, 2026

Demis Hassabis, chief executive officer of DeepMind Technologies
Image Credits:Jose Sarmento Matos/Bloomberg / Getty Images
  • Ram Iyer

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised $5 billion in a Series C funding round as it seeks to take its drug candidates to clinical trials.

The funding was co-led by Greenoaks and Sequoia Capital, with new investor Andreessen Horowitz and other investors also participating. All of the company’s existing backers, including Alphabet’s venture divisions GV and Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund, also invested.

Isomorphic Labs builds an AI drug-design engine that uses a slew of simulation AI models that explore various areas of chemistry to help the company design drugs. The company, whose work builds on DeepMind’s breakthrough AlphaFold protein-folding AI model, said its program has yielded “positive preclinical results” in oncology and immunology. The lab has struck deals with pharma giants like Eli Lilly, Novartis, and Johnson & Johnson.

The new funding, which comes on the heels of a $2.1 billion Series B round in May, will be used to continue developing its drug-design engine, as well as to foray into more types of medicine.

The Series C is Isomorphic’s first fundraise since its founder and CEO, Demis Hassabis, left his position as head of DeepMind to focus on drug discovery, which also saw him moving into a chairman role at DeepMind. Hassabis and then-director of DeepMind John Jumper won the Nobel Prize in chemistry for the lab’s work on AlphaFold, a system that predicts the 3D structure of proteins with nothing more than their genetic sequence.

Isomorphic did not disclose its new valuation. Bloomberg reported earlier this month that the lab was looking to raise funding at a $50 billion valuation.

来源: TechCrunch · AI · techcrunch.com